3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
Mucormycosis is a difficult to treat invasive fungal infection with high mortality.July 11, 2022, 3P Biopharmaceuticals (3P), a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO) has completed the manufacture of BSG005 biomass planned for Biosergen. Biosergen recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus. 3P and Biosergen have had a co-operation over several years building a strong partnership from the early years of process development